Trial Profile
Renvela® Post-Marketing Observational Study to Monitor the Clinical Use in Adult Hyperphosphataemic Chronic Kidney Disease Patients Not On Dialysis With Serum Phosphorus ≥1.78 mmol/L
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Sevelamer (Primary)
- Indications Hyperphosphataemia
- Focus Therapeutic Use
- Sponsors Genzyme Corporation
- 20 May 2014 New trial record